Information  X 
Enter a valid email address

Hipgnosis Songs Fund (SONG)

  Print      Mail a friend

Friday 07 December, 2018

Hipgnosis Songs Fund

Acquisition of Music Catalogue

RNS Number : 7501J
Hipgnosis Songs Fund Limited
07 December 2018
 

07 December 2018

Hipgnosis Songs Fund Limited ("Hipgnosis" or the "Company")

Acquisition of Music Catalogue

The Board of Hipgnosis Songs Fund Limited and its Investment Adviser, The Family (Music) Limited, are pleased to announce that the Company has acquired a music catalogue from TMS, an English songwriting and music production team comprised of Thomas 'Froe' Barnes, Benjamin Kohn and Peter 'Merf' Keller. The Company has acquired a 100% interest in the catalogue except for the writers' share of performance income.

 

The catalogue comprises 121 songs including 10 Top 5 UK singles with 5 Number 1 songs. The songs have appeared on 13 Top 5 UK albums including 7 Number 1 albums. It includes songs such as "Don't Be So Hard On Yourself" for Jess Glynne, "Wings" and "DNA" for Little Mix, ""Read All About It (Part 3) for Emeli Sandé, "Changing" for Sigma featuring Paloma Faith, "You're Nobody Till Somebody Loves You" for James Arthur, and others for Years And Years and Dua Lipa. The catalogue also includes the global Top 10 hit "Me, Myself & I" by G-Eazy and Bebe Rexha, which has been the recipient of both BMI and ASCAP Awards as a "Most Performed Work".

 

Merck Mercuriadis, Founder of The Family (Music) Limited and Hipgnosis Songs Fund Limited, said:

"Froe, Ben and Murf are highly intelligent songwriters that make terrific pop music which has resulted in 10 UK top 5 singles including five Number 1s. They have played a key role in developing the careers of Jess Glynne, Emeli Sandé, Little Mix and James Arthur amongst others and their songs feature on 7 Number 1 albums." 


TMS said:

"Having watched what Merck, Nile and Hipgnosis have been building, we're extremely impressed by all they've achieved in a very short space of time. The catalogues already acquired speak volumes about their ambition and it's nice to know that our songs will be sitting in some very esteemed company! We're super happy to be making this deal and pleased that these copyrights will be residing with the best possible custodians moving forward."

 

For further information, please contact:

 

The Family (Music) Limited

Merck Mercuriadis

 

Tel: +44 (0)1481 742742

N+1 Singer

James Maxwell / James Moat (Corporate Finance)

Alan Geeves / James Waterlow / Sam Greatrex (Sales)

 

Tel: +44 (0)20 7496 3000

The Outside Organisation

Alan Edwards / Nick Caley

Tel: +44 (0)7711 081 843

 

NOTES TO EDITORS

 

About Hipgnosis Songs Fund Limited

 

(www.hipgnosissongs.com)

 

Hipgnosis, which was founded by Merck Mercuriadis, is a Guernsey registered investment company established to offer investors a pure-play exposure to songs and associated musical intellectual property rights.  In its Initial Public Offering on the Specialist Fund Segment of the London Stock Exchange's main market on 11 July 2018, the Company raised approximately £200m gross equity capital.

 

About The Family (Music) Limited

 

The Company's Investment Adviser is The Family (Music) Limited, which was founded by Merck Mercuriadis, former manager of globally successful recording artists, such as Elton John, Guns N' Roses, Morrissey, Iron Maiden and Beyoncé, and hit songwriters such as Diane Warren, Justin Tranter and The-Dream, and former CEO of The Sanctuary Group plc.  The Investment Adviser has assembled an Advisory Board of highly successful music industry experts which include award winning members of the artist, songwriter, publishing, legal, financial, recorded music and music management communities, all with in-depth knowledge of music publishing. Members of The Family (Music) Limited Advisory Board include Nile Rodgers, The-Dream, Bill Leibowitz, Ian Montone, and Jason Flom.

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
ACQTFBJTMBJMTPP

a d v e r t i s e m e n t